Who makes Cabrilizumab?

Cabrilizumab is developed by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

What development phase is Cabrilizumab in?

Cabrilizumab is in discontinued.

Last reviewed 2026-04-19 · How we verify

Cabrilizumab

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · discontinued Small molecule

At a glance

Generic name	Cabrilizumab
Also known as	FPA008, BMS-986227
Sponsor	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Modality	Small molecule
Therapeutic area	Other
Phase	discontinued

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Safety and Tolerability Study of Combination Nivolumab and Cabiralizumab as Neoadjuvant and Adjuvant Therapy for Resectable Biliary Tract Cancer (Phase 2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Cabrilizumab CI brief — competitive landscape report
Cabrilizumab updates RSS · CI watch RSS
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins portfolio CI